Stock Markets February 10, 2026

Market Movers: Tech and Financials Lead Tuesday Swings as Biotech Names Rally

A mixed session sees big declines among major banks and chipmaker Intel, while select software and small-cap biotech stocks post strong gains

By Jordan Park INTC WFC MS BAC C
Market Movers: Tech and Financials Lead Tuesday Swings as Biotech Names Rally
INTC WFC MS BAC C

Tuesday's trading session produced wide dispersion across market capitalizations. Large financial and semiconductor names recorded notable declines, while software and several smaller biotechnology and specialty-equipment companies posted meaningful advances. The moves were driven by company-specific news and earnings-related reactions rather than a single market catalyst.

Key Points

  • Major financial firms and Intel were among the larger decliners in the mega-cap group, while Oracle and Home Depot posted gains.
  • Large- and mid-cap moves were driven largely by earnings results, guidance reactions, analyst actions, and takeover-related news.
  • Small-cap biotech and specialty-equipment names saw the largest percentage gains, with clinical trial success and analyst upgrades noted as proximate catalysts.

Equity markets on Tuesday displayed pronounced divergence across sectors and market-cap tiers. Several big-cap financials and a major chipmaker fell sharply, while enterprise software firms and a number of small-cap biotech and industrials posted double-digit advances. Below is a categorized review of the most significant movers, with an emphasis on the specific company developments cited by market participants.


Session highlights

The session was marked by concentrated reactions to corporate updates and analyst commentary. Among mega-cap stocks, Intel Corp recorded a meaningful decline while Oracle Corp and Home Depot advanced. In the large-cap and mid-cap universe, several financial-services firms sold off, while select technology and industrial names saw positive momentum. Small-cap biotechs and specialty-equipment issuers included some of the largest percentage winners.


Mega-cap movers ($200 billion USD or higher)

  • Intel Corp (INTC) - Mobileye to supply advanced driver assistance systems to Mahindra; -5.56%
  • Wells Fargo (WFC) -4.61%
  • Morgan Stanley (MS) -4.3%
  • Bank Of America (BAC) -3.6%
  • Citigroup (C) -3.01%
  • Palantir Technologies Inc (PLTR) -2.74%
  • Micron Tech (MU) -1.88%
  • Oracle Corp (ORCL) +3.69%
  • Home Depot (HD) +2.56%
  • Alibaba-exch (BABA) +2.16%

The declines among major banks and Intel contrasted with gains in enterprise software and retail names. Intel's move was tied to a Mobileye supply announcement for Mahindra, noted here as the market's proximate piece of news accompanying the stock's drop.


Large-cap movers ($10-$200 billion USD)

  • Medpace Holdings Inc (MEDP) - Medpace shares tumble 5% despite Q4 earnings beat, in-line guidance; -14.05%
  • LPL Investment Ho (LPLA) -10.45%
  • Raymond James Financial Inc (RJF) -8.68%
  • Charles Schwab (SCHW) -8.56%
  • Spotify Technology (SPOT) +15.57%
  • Datadog Inc (DDOG) +14.46%
  • Credo Technology Holding (CRDO) - Credo technology expects Q3 revenue above guidance, projects 200% growth; +10.46%
  • Entegris Inc. (ENTG) - Entegris shares rise 7% after beating Q4 expectations; +10.51%
  • Figma Inc (FIG) +9.31%
  • Masco Corp (MAS) - Masco shares rise 4% as 2026 outlook tops expectations; +9.13%

Within this cohort, reaction to earnings and guidance drove outsized moves. Medpace declined significantly even after an earnings beat because forward guidance was characterized as in-line by the market. Conversely, several technology and industrial names rallied following beats or upward-tilted outlooks.


Mid-cap movers ($2-$10 billion USD)

  • Unifirst Corp (UNF) - UniFirst and Cintas renew takeover discussions at $275 per share - Bloomberg; +19.41%
  • Ultra Clean Holdi (UCTT) +11.45%
  • Kyndryl Holdings (KD) - Guggenheim downgrades Kyndryl stock rating to Neutral on management exits; +10.62%
  • Hesai ADR (HSAI) +8.17%
  • Ringcentral Inc (RNG) +6.89%
  • Under Armour (UAA) -8.65%
  • Zoominfo Technologies Inc (GTM) - ZoomInfo shares tumble as in-line guidance disappoints investors; -9.22%
  • Amentum Holdings LLC (AMTM) - Amentum shares fall plunge 8% as fiscal 2026 guidance trails estimates; -13.09%
  • Goodyear Tire (GT) - Goodyear Tire shares fall 6% after posting mixed Q4 results; -13.17%
  • Upwork (UPWK) - Upwork shares plunge 21% as Q1 guidance disappoints investors; -13.78%

Mid-cap performance was mixed: takeover chatter boosted UniFirst, while disappointing forward guidance and analyst actions weighed on other names. Several companies experienced investor rotation tied directly to guidance or analyst commentary.


Small-cap movers ($300 million - $2 billion USD)

  • Evommune (EVMN) - Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial; +78.47%
  • Nektar Therapeutics (NKTR) - William Blair upgrades Nektar Therapeutics stock rating to Outperform; +40.54%
  • Ichor Holdings Ltd (ICHR) - Ichor shares soar as Q4 results beat estimates, guidance tops expectations; +32.16%
  • Neumora Therapeutics (NMRA) +24.78%
  • Lumexa Imaging Holdings Corp (LMRI) +20.78%
  • PepGen (PEPG) +19.95%
  • Vestis (VSTS) - Vestis misses first quarter expectations as revenue falls 3% YoY; +20.49%
  • Gilat Satellite N (GILT) -21.19%
  • Jumia Technologies AG (JMIA) -16.87%
  • Regenxbio Inc (RGNX) -17.27%

Small-cap activity was particularly notable in biotech and specialized equipment. Clinical news propelled Evommune higher after a phase 2a primary endpoint readout, while analyst upgrades and beat-and-raise results supported other gains. At the same time, several small caps posted steep declines.


Conclusion

Tuesday's movers reflect a market responding to idiosyncratic corporate developments - earnings beats or misses, guidance changes, analyst ratings, takeover chatter, and clinical trial news. That dispersion underscores the importance of parsing company-level catalysts rather than attributing moves to a single, broad market factor.

Risks

  • Forward guidance that falls short of expectations can trigger steep share-price declines, impacting financials and services companies.
  • Earnings beats do not guarantee positive price action if guidance is perceived as cautious, as illustrated by Medpace in the large-cap group.
  • Clinical or trial readouts, while bullish when positive, can create concentrated volatility in small-cap biotech stocks.

More from Stock Markets

S&P 500 Shows Signs of Tightening Range; Strategist Sees Potential for a Big Move Feb 22, 2026 Supreme Court to Clarify Reach of Helms-Burton Act in Multi-Billion Dollar Cuba Claims Feb 22, 2026 Switzerland Pulling Ahead in Early Economic Gains from AI Feb 22, 2026 Nvidia Results and Software Earnings to Test AI-Driven Market Sentiment Feb 22, 2026 Analysts Shift AI Bets: Nvidia, Amazon, Dell, Analog Devices, Shopify See Upgrades and Bullish Casework Feb 22, 2026